Proceedings · Session S-431 · filed November 18, 2026
Translational ScienceSession paper
Alcohol Cut Anti-PD-1 Efficacy Roughly 50% in Mouse Cancer Models
Mouse studies show alcohol halved anti-PD-1 efficacy and raised recurrence; anti-TIGIT antibodies restored response. Lung cancer patients drinking 8+ weekly drinks had poorer survival.
By Tom Whitfield3 min read597 words
Summary
- Alcohol reduced anti-PD-1 efficacy by roughly 50% in mouse lung and bladder cancer models (Science Signaling, UNC Chapel Hill)
- Patients self-reporting 8+ drinks a week had poorer survival on immune checkpoint inhibitors; definitive only in lung cancer
- Anti-TIGIT antibodies fully restored anti-PD-1 efficacy in mice; SREBP inhibition with betulin helped to a lesser extent
- Up to 76.4% of cancer patients still drink, per recent studies cited in the paper
- Ethanol shifted CD4+ T cells toward a Th17 profile and increased TIGIT-expressing T cells in MB49 bladder tumors

Regular alcohol use roughly halved the efficacy of anti-PD-1 immunotherapy in mouse models of lung and bladder cancer, according to researchers at the University of North Carolina at Chapel Hill. The study, published in Science Signaling under the title "Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity," also tracked poorer survival in a retrospective patient cohort — but only in lung cancer, where the data were strong enough to call definitive.
The stakes are real. Up to 76.4% of patients with cancer still drink, the paper's authors note, citing recent studies. Immune checkpoint inhibition has improved outcomes for some patients with advanced cancers, yet relatively few achieve a complete response. Medical societies have already called for more research on how alcohol affects treatment outcomes. This paper is a first mechanistic answer, at least in mice.
What did the mouse experiments measure?
The UNC team dosed mouse models of lung and bladder cancer with a moderate-to-heavy amount of ethanol while treating them with anti-PD-1 antibodies. Two hard results followed: alcohol reduced immunotherapy efficacy by roughly 50% in both models, and it increased tumor recurrence.
The mechanistic work centered on mice with MB49 bladder tumors. There, ethanol:
- reduced the number of tumor-infiltrating T cells;
- shifted tumor-associated CD4+ T cells toward a T helper 17 profile, away from a T helper 1 profile;
- reduced tissue-resident memory T cells;
- increased the proportion of T cells expressing TIGIT, an alternative immune checkpoint receptor;
- induced SREBP-mediated lipid signaling in tumor-associated T cells.
That last detail matters for anyone thinking about drug combinations. SREBP signaling is druggable. TIGIT is already a clinical target with antibodies in development.
Can the damage be reversed?
Partly, and the numbers rank the interventions. Blocking TIGIT with antibodies restored the efficacy of anti-PD-1 treatment in the animals. Inhibiting SREBP signaling with betulin improved it, but to a lesser extent. TIGIT blockade was the stronger lever in this system.
One caveat for translational readers: these are mouse results, from two tumor models, at moderate-to-heavy ethanol exposure. The authors don't claim equivalence to human drinking patterns, and the mouse work measured efficacy and recurrence — not survival.
What did the patient data show?
The retrospective cohort covered patients with skin, lung, bladder, or head and neck cancer treated with immune checkpoint inhibitors. Patients who self-reported eight or more drinks a week had poorer survival after starting treatment. In lung cancer specifically, regular alcohol use was associated with a reduced survival benefit from checkpoint inhibition.
The signal weakened beyond lung cancer. For the other tumor types, the researchers describe the effects as less definitive — not because the biology cleared alcohol, but because alcohol use reporting was too limited. Retrospective self-report is the weak link here, and the authors say so implicitly by calling for better data capture.
"This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention," Gilley et al. wrote.
What comes next?
The authors propose folding patient alcohol use into cancer databases, which would let researchers measure its effect on outcomes across CAR T cell therapy, chemotherapy, and radiation in multiple cancers. Until those datasets exist, the actionable takeaway for oncology teams is modest but concrete: eight-plus drinks a week is a measurable risk factor in lung cancer checkpoint therapy, and a TIGIT-blocking combination is the lead candidate to counter it in preclinical work.
via science.org (Original)
Filed under
- cancer-immunotherapy
- anti-pd-1
- alcohol-use
- tumor-immunity
- tigit
More from Tom Whitfield
Show full bio
Senior reporter covering technology and product news in research and development at Hypothesis Wire.
268 articles
References
- CAR-T in Bladder Cancer and Misread Spectra: This Week's Two Big R&D Stories
- Merck-Moderna melanoma vaccine cuts recurrence risk 42% at ESMO 2026
- DUSP4 protein keeps CAR-T cells killing colorectal tumours, NUS study finds
- BCG Vaccine Cut Tau Tangles and Restored Memory in Dementia Mice
- City of Hope Team Identifies Immune Pathway Behind Radiation Lung Damage